Clinical and Translational Oncology

, Volume 14, Issue 11, pp 803–811

miRNAs as biomarkers in prostate cancer

Authors

  • Irene Casanova-Salas
    • Laboratory of Molecular BiologyFundacion Instituto Valenciano de Oncologia
  • José Rubio-Briones
    • Department of UrologyFundacion Instituto Valenciano de Oncologia
  • Antonio Fernández-Serra
    • Laboratory of Molecular BiologyFundacion Instituto Valenciano de Oncologia
    • Laboratory of Molecular BiologyFundacion Instituto Valenciano de Oncologia
Educational Series - Blue Series Advances in Translational Oncology

DOI: 10.1007/s12094-012-0877-0

Cite this article as:
Casanova-Salas, I., Rubio-Briones, J., Fernández-Serra, A. et al. Clin Transl Oncol (2012) 14: 803. doi:10.1007/s12094-012-0877-0

Abstract

Current prostate cancer (PCa) diagnosis is based in the serum prostate-specific antigen biomarker and digital rectal examination. However, these methods are limited by a low predictive value (24–37 %) and a high risk of mistaken results. During last years, new promising biomarkers such as Prostate Cancer Antigen 3 (PCA-3) and TMPRSS2-ETS fusion genes have been evaluated for their clinical use. However, the search of new biomarkers that could be used for PCa diagnosis and prognosis is still needed. Recent studies have demonstrated that the aberrant expression of microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, is related with the development of several cancers, including PCa. Since miRNAs serve as phenotypic signatures of different cancers, they appear as potential diagnostic, prognostic and therapeutic tools. Here, we review the current knowledge of miRNA expression patterns in PCa and their role in PCa prognosis and therapeutics.

Keywords

Prostate cancer Biomarker MicroRNA

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012